Advertisement

Related Videos

Peter Clark, MA, MD, FRCP: A Payer Perspective

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Advertisement

Advertisement




Nov
12
Today In Oncology
Local Consolidative Therapy Enhances Outcomes With Osimertinib in EGFR-Mutant NSCLC
Final FLAURA2 Analysis Confirms First-Line Benefit of Osimertinib-Chemotherapy in EGFR-Positive NSCLC
Routine AI Assistance May Lead to Loss of Skills in Endoscopists, Study Shows
How to Adapt to the Era of AI and the Changing Interactions With Patients: Lessons From a Low-Resource Setting
HER3-DXd in Patients With Active Brain Metastases From NSCLC and Breast Cancer
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo